Skip to main content
. 2022 Oct 27;7(2):196–204. doi: 10.1182/bloodadvances.2022007791

Figure 3.

Figure 3.

Kaplan-Meier curves for survival outcomes, starting from day 1 of the DI course, for patients who received <4 (blue) or ≥4 (red) doses of PEG-asparaginase. (A) OS for patients with standard-risk ALL, (B) EFS for patients with standard-risk ALL, (C) OS for patients with high-risk ALL, and (D) EFS for patients with high-risk ALL.